United States - English - NLM (National Library of Medicine)

roerig - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin 100 mg in 1 ml - unasyn is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli ,2 klebsiella spp.2 (including k. pneumoniae 2), proteus mirabilis ,2 bacteroides fragilis ,2 enterobacter spp.,2 and acinetobacter calcoaceticus. 2 note: for information on use in pediatric patients (see precautions-pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae 2), bacteroides spp. (including b. fragilis ), and enterobacter spp.2 gynecological infections caused by beta-lactamase producing strains of escherichia coli, 2 and bacteroides spp.2 (including b. fragilis 2). while unasyn is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to tr

United States - English - NLM (National Library of Medicine)

meitheal pharmaceuticals inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli ,* klebsiella spp.* (including k. pneumoniae *), proteus mirabilis ,* bacteroides fragilis ,* enterobacter spp.,* and acinetobacter calcoaceticus .* note: for information on use in pediatric patients (see precautions - pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae *), bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli ,* and bacteroides spp.* (including b. fragilis *). * efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampicillin and sulbactam for injection is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with ampicillin and sulbactam for injection due to its ampicillin content. therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to ampicillin and sulbactam for injection should not require the addition of another antibacterial. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to ampicillin and sulbactam for injection. therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. once the results are known, therapy should be adjusted if appropriate. to reduce the development of drug-resistant bacteria and maintain effectiveness of ampicillin and sulbactam for injection and other antibacterial drugs, ampicillin and sulbactam for injection should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. the use of ampicillin and sulbactam for injection is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or stevens-johnson syndrome) to ampicillin, sulbactam or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins). ampicillin and sulbactam for injection is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with ampicillin and sulbactam for injection.

United States - English - NLM (National Library of Medicine)

meitheal pharmaceuticals inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli ,* klebsiella spp.* (including k. pneumoniae *), proteus mirabilis ,* bacteroides fragilis ,* enterobacter spp.,* and acinetobacter calcoaceticus .* note: for information on use in pediatric patients (see precautions - pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae *), bacteroides spp. (including b. fragilis ), and enterobacter spp * gynecological infections caused by beta-lactamase producing strains of escherichia coli ,* and bacteroides spp.* (including b. fragilis *). * efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampicillin and sulbactam for injection is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with ampicillin and sulbactam for injection due to its ampicillin content. therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to ampicillin and sulbactam for injection should not require the addition of another antibacterial. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to ampicillin and sulbactam for injection. therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. once the results are known, therapy should be adjusted if appropriate. to reduce the development of drug-resistant bacteria and maintain effectiveness of ampicillin and sulbactam for injection and other antibacterial drugs, ampicillin and sulbactam for injection should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. the use of ampicillin and sulbactam for injection is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or stevens-johnson syndrome) to ampicillin, sulbactam or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins). ampicillin and sulbactam for injection is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with ampicillin and sulbactam for injection.

United States - English - NLM (National Library of Medicine)

xellia pharmaceuticals usa llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli ,2 klebsiella spp.2 (including k. pneumoniae2 ), proteus mirabilis ,2 bacteroides fragilis ,2 enterobacter spp.,2 and acinetobacter calcoaceticus.2 note: for information on use in pediatric patients (see precautions-pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae2 ), bacteroides spp. (including b. fragilis ), and enterobacter spp.2 gynecological infections caused by beta-lactamase producing strains of escherichia coli,2 and bacteroides spp.2 (including b. fragilis2 ). while ampicillin and sulbactam for injection, usp is indicated only for the conditions listed above, infe

United States - English - NLM (National Library of Medicine)

xellia pharmaceuticals usa llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli ,2 klebsiella spp.2 (including k. pneumoniae2 ), proteus mirabilis ,2 bacteroides fragilis ,2 enterobacter spp.,2 and acinetobacter calcoaceticus.2 note: for information on use in pediatric patients (see precautions–pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae2 ), bacteroides spp. (including b. fragilis ), and enterobacter spp.2 gynecological infections caused by beta-lactamase producing strains of escherichia coli,2 and bacteroides spp.2 (including b. fragilis2 ). while ampicillin and sulbactam for injection, usp is indicated only for the conditions listed above

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - ampicillin as sodium 500 mg; sulbactam as sodium 250 mg - powder for solution for injection - ampicillin and enzyme inhibitor - sulbactam sodium/ampicillin sodium im/iv is indicated for the treatment of infections due to susceptible beta-lactamase producing strains of microorganisms in the following conditions: 1) skin and skin structure infections. 2) intra-abdominal infections. 3) gynecological infections.

United States - English - NLM (National Library of Medicine)

agila specialties private limited - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin 10 g in 15 g

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - indications and usage: ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli,* klebsiella spp.* (including k. pneumoniae* ), proteus mirabilis,* bacteroides fragilis,* enterobacter spp.,* and acinetobacter calcoaceticus .* note: for information on use in pediatric patients see precautions, pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae* ), bacteroides spp. (including b. fr

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli* , klebsiella spp.* (including k. pneumoniae *), proteus mirabilis* , bacteroides fragilis* , enterobacter spp.*, and acinetobacter calcoaceticus*. note: for information on use in pediatric patients see precautions-pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae* ), bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli*, and bacteroides spp.* (including b. fragilis* ). *efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampici

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin and sulbactam for injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli* , klebsiella spp.* (including k. pneumoniae* ), proteus mirabilis*, bacteroides fragilis*, enterobacter spp.*, and acinetobacter calcoaceticus*. note: for information on use in pediatric patients see precautions-pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae* ), bacteroides spp. (including b. fragilis ), and enterobacter spp.*. gynecological infections caused by beta-lactamase producing strains of escherichia coli*, and bacteroides spp.* (including b. fragilis*). *efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampicillin and sul